206 related articles for article (PubMed ID: 29222021)
1. Identification and validation of salivary proteomic signatures for non-invasive detection of ovarian cancer.
Tajmul M; Parween F; Singh L; Mathur SR; Sharma JB; Kumar S; Sharma DN; Yadav S
Int J Biol Macromol; 2018 Mar; 108():503-514. PubMed ID: 29222021
[TBL] [Abstract][Full Text] [Related]
2. MALDI-TOF-MS analysis in discovery and identification of serum proteomic patterns of ovarian cancer.
Swiatly A; Horala A; Hajduk J; Matysiak J; Nowak-Markwitz E; Kokot ZJ
BMC Cancer; 2017 Jul; 17(1):472. PubMed ID: 28683725
[TBL] [Abstract][Full Text] [Related]
3. Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies.
Timms JF; Arslan-Low E; Kabir M; Worthington J; Camuzeaux S; Sinclair J; Szaub J; Afrough B; Podust VN; Fourkala EO; Cubizolles M; Kronenberg F; Fung ET; Gentry-Maharaj A; Menon U; Jacobs I
Proteomics Clin Appl; 2014 Dec; 8(11-12):982-93. PubMed ID: 25290619
[TBL] [Abstract][Full Text] [Related]
4. Identification of ovarian cancer-associated proteins in symptomatic women: A novel method for semi-quantitative plasma proteomics.
Shield-Artin KL; Bailey MJ; Oliva K; Liovic AK; Barker G; Dellios NL; Reisman S; Ayhan M; Rice GE
Proteomics Clin Appl; 2012 Apr; 6(3-4):170-81. PubMed ID: 22532453
[TBL] [Abstract][Full Text] [Related]
5. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer.
Jou YJ; Lin CD; Lai CH; Chen CH; Kao JY; Chen SY; Tsai MH; Huang SH; Lin CW
Anal Chim Acta; 2010 Nov; 681(1-2):41-8. PubMed ID: 21035601
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of proteomics-identified CCL18 and CXCL1 as circulating tumor markers for differential diagnosis between ovarian carcinomas and benign pelvic masses.
Wang Q; Li D; Zhang W; Tang B; Li QQ; Li L
Int J Biol Markers; 2011; 26(4):262-73. PubMed ID: 21928244
[TBL] [Abstract][Full Text] [Related]
7. Identification of differentially-expressed proteins between early submucosal non-invasive and invasive colorectal cancer using 2D-DIGE and mass spectrometry.
Zhang J; Song MQ; Zhu JS; Zhou Z; Xu ZP; Chen WX; Chen NW
Int J Immunopathol Pharmacol; 2011; 24(4):849-59. PubMed ID: 22230392
[TBL] [Abstract][Full Text] [Related]
8. Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging.
Sinclair J; Metodieva G; Dafou D; Gayther SA; Timms JF
J Proteomics; 2011 Apr; 74(4):451-65. PubMed ID: 21237297
[TBL] [Abstract][Full Text] [Related]
9. Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Haslene-Hox H; Oveland E; Woie K; Salvesen HB; Wiig H; Tenstad O
Biochim Biophys Acta; 2013 Nov; 1834(11):2347-59. PubMed ID: 23707566
[TBL] [Abstract][Full Text] [Related]
10. Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array.
Vathipadiekal V; Wang V; Wei W; Waldron L; Drapkin R; Gillette M; Skates S; Birrer M
Clin Cancer Res; 2015 Nov; 21(21):4960-9. PubMed ID: 25944803
[TBL] [Abstract][Full Text] [Related]
11. Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.
Lee YH; Kim JH; Zhou H; Kim BW; Wong DT
J Mol Med (Berl); 2012 Apr; 90(4):427-34. PubMed ID: 22095100
[TBL] [Abstract][Full Text] [Related]
12. Haptoglobin-alpha subunit as potential serum biomarker in ovarian cancer: identification and characterization using proteomic profiling and mass spectrometry.
Ye B; Cramer DW; Skates SJ; Gygi SP; Pratomo V; Fu L; Horick NK; Licklider LJ; Schorge JO; Berkowitz RS; Mok SC
Clin Cancer Res; 2003 Aug; 9(8):2904-11. PubMed ID: 12912935
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteome analysis of ovarian cancer tissues using a iTRAQ approach.
Wang LN; Tong SW; Hu HD; Ye F; Li SL; Ren H; Zhang DZ; Xiang R; Yang YX
J Cell Biochem; 2012 Dec; 113(12):3762-72. PubMed ID: 22807371
[TBL] [Abstract][Full Text] [Related]
14. Potential predictive plasma biomarkers for cervical cancer by 2D-DIGE proteomics and Ingenuity Pathway Analysis.
Guo X; Hao Y; Kamilijiang M; Hasimu A; Yuan J; Wu G; Reyimu H; Kadeer N; Abudula A
Tumour Biol; 2015 Mar; 36(3):1711-20. PubMed ID: 25427637
[TBL] [Abstract][Full Text] [Related]
15. Identification of serum biomarkers for ovarian cancer using MALDI-TOF-MS combined with magnetic beads.
Wu S; Xu K; Chen G; Zhang J; Liu Z; Xie X
Int J Clin Oncol; 2012 Apr; 17(2):89-95. PubMed ID: 21638024
[TBL] [Abstract][Full Text] [Related]
16. Ovarian cancer circulating extracelluar vesicles promote coagulation and have a potential in diagnosis: an iTRAQ based proteomic analysis.
Zhang W; Peng P; Ou X; Shen K; Wu X
BMC Cancer; 2019 Nov; 19(1):1095. PubMed ID: 31718609
[TBL] [Abstract][Full Text] [Related]
17. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer.
Kong F; Nicole White C; Xiao X; Feng Y; Xu C; He D; Zhang Z; Yu Y
Gynecol Oncol; 2006 Feb; 100(2):247-53. PubMed ID: 16229881
[TBL] [Abstract][Full Text] [Related]
18. Proteomic studies of early-stage and advanced ovarian cancer patients.
Wang J; Zhang X; Ge X; Guo H; Xiong G; Zhu Y
Gynecol Oncol; 2008 Oct; 111(1):111-9. PubMed ID: 18703221
[TBL] [Abstract][Full Text] [Related]
19. Proteomics-based identification of tumor relevant proteins in lung adenocarcinoma.
Zhou X; Xue L; Hao L; Liu S; Zhou F; Xiong H; Qi X; Lin D; Shao S
Biomed Pharmacother; 2013 Sep; 67(7):621-7. PubMed ID: 23916545
[TBL] [Abstract][Full Text] [Related]
20. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages.
Jou YJ; Lin CD; Lai CH; Tang CH; Huang SH; Tsai MH; Chen SY; Kao JY; Lin CW
Clin Chim Acta; 2011 Jul; 412(15-16):1357-65. PubMed ID: 21497587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
